Streamlining Rheumatology Prior Authorizations with Magellan Healthcare

Klivira's platform is engineered to automate and accelerate the complex prior authorization workflows inherent in rheumatology, specifically when interacting with Magellan Healthcare's utilization management processes.

Revenue cycle leaders and prior authorization coordinators face significant challenges managing the high volume and intricate requirements of rheumatology PAs. For treatments managed by Magellan Healthcare, a Centene-owned utilization management entity, these complexities are amplified by specific policy adherence and documentation demands for high-cost biologics and specialty drugs.

The Intersection of Rheumatology and Magellan Healthcare PA

Rheumatology is characterized by the chronic management of autoimmune diseases such as Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), and Lupus, frequently requiring high-cost biologic and targeted therapies. Magellan Healthcare, as a utilization management provider, applies specific clinical criteria and step therapy protocols to these agents, impacting patient access and provider workflows.

Key Prior Authorization Triggers in Rheumatology with Magellan Healthcare

Biologics (e.g., TNF-alpha inhibitors like adalimumab, etanercept, infliximab; non-TNF biologics like IL-6, IL-17, IL-23 inhibitors)
JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib)
Specialty drugs for specific indications (e.g., anifrolumab for SLE, belimumab for SLE)
Infusion therapy for provider-administered biologics
Advanced imaging (e.g., MRI for inflammatory arthritis, ultrasound-guided injections)
DEXA scans for osteoporosis management in chronic steroid patients

Navigating Magellan Healthcare's Documentation Requirements for Rheumatology

Magellan Healthcare's PA requirements for rheumatology treatments are typically aligned with evidence-based guidelines such as the ACR Treatment Guidelines. Providers must meticulously document diagnosis criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA), disease activity scores (e.g., DAS28, CDAI, SDAI), prior conventional DMARD trials, and completion of required screenings (e.g., TB, hepatitis B/C) to justify the medical necessity of advanced therapies.

Common Prior Authorization Denial Reasons with Magellan Healthcare in Rheumatology

Failure to document completion of required step therapy sequences
Lack of documentation for biosimilar substitution trials where mandated
Absence of current disease activity scores (e.g., DAS28, PASI) in the clinical record
Insufficient duration or trial of conservative care or conventional DMARDs
Incomplete or missing pre-initiation screening documentation (e.g., TB, hepatitis)
Request for off-indication use without specific payer policy support

Klivira's Approach to Rheumatology Prior Authorizations for Magellan Healthcare

Klivira's platform provides specialized automation for rheumatology PAs, incorporating ACR-guideline-aware policy logic for step therapy sequencing and biosimilar substitution routing. Our system streamlines periodic re-authorization workflows for chronic treatments and manages the medical-vs-pharmacy benefit split for the same agent, ensuring efficient submission to Magellan Healthcare.

Integrating with Magellan Healthcare for Rheumatology Workflows

Klivira integrates directly with EMR systems via standards like SMART on FHIR, extracting relevant clinical data points required for Magellan Healthcare submissions. This data is then used to auto-populate X12 278 transactions or ePA forms, facilitating rapid and accurate submission through Magellan's preferred channels, minimizing manual data entry and accelerating decision times for critical rheumatology treatments.

Frequently asked questions

How does Klivira handle step therapy requirements specific to Magellan Healthcare for rheumatology biologics?

Klivira's platform incorporates payer-specific policy logic, including Magellan Healthcare's step therapy protocols. It guides users through the required sequence of prior agent trials and biosimilar substitutions, ensuring documentation aligns with Magellan's criteria before submission.

What EMR systems can Klivira integrate with to streamline rheumatology PAs for Magellan?

Klivira offers robust integration capabilities with major EMR systems using standards like SMART on FHIR. This allows for seamless extraction of patient demographics, diagnoses, medication history, and clinical notes to support rheumatology PA submissions to Magellan Healthcare.

Does Klivira support re-authorization workflows for chronic rheumatology treatments managed by Magellan?

Yes, Klivira is designed to manage the ongoing burden of chronic treatment re-authorizations. Our system tracks re-authorization due dates and prompts for the necessary continuous response documentation, ensuring timely resubmission to Magellan Healthcare for continued patient care.

How does Klivira manage the distinction between medical and pharmacy benefit for rheumatology drugs under Magellan?

Klivira's platform intelligently routes prior authorization requests based on the specific drug, administration mode (self-administered vs. provider-administered), and payer policy. This ensures that the correct benefit channel (medical or pharmacy) is engaged for Magellan Healthcare submissions.

What are the common challenges in rheumatology PA with Magellan Healthcare?

Common challenges include navigating complex step therapy requirements, ensuring proper biosimilar substitution, documenting specific disease activity scores, and managing the high volume of chronic treatment re-authorizations, all while adhering to Magellan Healthcare's specific utilization management criteria.